Confirmed Speakers

4th International RASopathies Symposium, July 17-19, 2015, Seattle, WA

Co-Chairs

  • David Stevenson, MD, Stanford University, CA
  • Brigitte Widemann, MD, National Cancer Institute, Bethesda, MD

Speakers and Moderators

 

Rosemary Anderson, President
NF Michigan, Grand Rapids, MI, USA
Advocates’ Panel
Brage Andresen, PhD
University of S. Denmark, Odense, Denmark
Alternative Splicing Therapeutics – HRAS
Annette Bakker, PhD
Children’s Tumor Foundation, NY, USA
Co-Moderator, Collaborations, Industry, and Funding; Business Model
Pinar Bayrak-Toydemir, MD, PhD
University of Utah, Salt Lake City, UT, USA
RASA 1
Tammy Bowers, Advocate
NSML/LEOPARD syndrome, UT, USA
Co-Moderator, Advocates’ Panel
Emma Burkitt-Wright, MBChB
St. Mary’s Hospital, Manchester, UK
Co-Moderator, Clinical Trails in RASopathies: Design, Endpoints, and Results
Kathryn Chatfield, MD, PhD
University of Colorado, Denver, CO, USA
Cardiac Manifestations
Judy Doyle, Board Member
CFC International, Media, OH, USA
Advocates’ Panel
Florent Elefteriou, PhD
Vanderbilt University, Nashville, TN, USA
Co-Moderator, Preclinical Studies
Ype Elgersma, PhD
Erasmus University Medical Center, Rotterdam, The Netherlands
Cognition/Learning
 Michelle Ellis, Director
Noonan UK, London, UK
 Advocates’ Panel
Michael Fisher, MD
Children’s Hospital Philadelphia, PA, USA
Agents Targeting RAS/MAPK in Clinical Development: Current Status
David Franz, MD
Cincinnati Children’s Hospital, OH, USA
TSC
Bruce Gelb, MD
Mt. Sinai School of Medicine, New York, NY, USA
Drug Target Screening – Drosophila
Anne Goriely, PhD
University of Oxford, UK
Co-Moderator, Preclinical Studies
Karen Gripp, MD
A.I.duPont Hospital for Children, Wilmington, DE, USA
 Co-Moderator, Abstracts by Young Investigators
Rick Guidotti
Positive Exposure
 Photo shoot (Saturday)
2015 Symposium RASopathies Photography (Sunday)
Antonio Hardan, MD
Stanford University, Stanford, CA, USA
PTEN
Marguerite Hutchinson, JD
Plexxicon, Berkeley, CA, USA
Panelist, Collaborations, Industry, and Funding
Kim Keppler-Noreuil, MD
National Human Genome Research Institute, Bethesda, MD, USA
PIK3CA Conditions
Bronwyn Kerr, MD
University of Manchester, UK
Co-Moderator, RASopathy Phenotypes (Shared and Discordant)
Bruce Korf, MD, PhD
University of Alabama, Birmingham, AL, USA
Cancer
Chiara Leoni, MD
Università Cattolica Sacro Cuore, Rome, Italy
Co-Moderator, RASopathy Phenotypes (Shared and Discordant)
Ram Mandalam, President and CEO
Cellerant, San Carlos, CA, USA
Panelist, Collaborations, Industry, and Funding
Andre Marozsan, Interim Director, Pre-Clinical Pharmacology
Alexion, Cheshire, CT, USA
Panelist, Collaborations, Industry, and Funding
Frank McCormick, PhD, FRS, DSc (Hon)
University of California, San Francisco, CA, USA
Keynote Speaker
Rene Pierpont, PhD
University of Minnesota, Minneapolis, USA
Post-Symposium Noonan Syndrome Meeting
Scott Plotkin, MD, PhD
Massachusetts General Hospital, Boston, MA, USA
Co-Moderator, Clinical rails in RASopathies: Design, Endpoints, and Results; Trial Design Using Individualized Endpoints
Katherine A. Rauen
University of California at Davis, CA, USA
MEK Inhibitors for Strength
Karlyne Reilly, PhD
National Cancer Institute, Bethesda, MD, USA
NF1 Preclinical Models and Trials
Amy Roberts, MD
Children’s Hospital Boston, MA, USA
TRND Study; Co-Moderator, Abstracts by Young Investigators
Abby Sandler, PhD
National Cancer Institute, Bethesda, MD, USA
NCI Rare Disease Initiative
Lisa Schill, BS
RASopathies Network USA, Williamstown, NJ, USA
Co-PI; Co-Moderator, Collaborations, Industry, and Funding
Lisa Schoyer, MFA
RASopathies Network USA, Altadena, CA
PI; Co-Moderator, Advocates’ Panel
Suzanne Schrandt, JD
Patient-Centered Outcomes Research Institute (PCORI), Washington, DC
PCORI:  Engaging Patients Across the Research Continuum
Dawn Siegel, MD
Children’s Hospital of Wisconsin, Milwaukee, WI, USA
Moderator, RASopathies Cousins
Alison Silva, EVP & COO
Synlogic, Cambridge, MA, USA
Panelist, Collaborations, Industry, and Funding
Patroula Smpokou, MD
Children’s National Health System, Washington, DC, USA
Post-Symposium Noonan Syndrome Meeting
David Stevenson, MD
Stanford University, Stanford, CA, USA
Symposium Co-Chair; Overview of the RASopathies
Angelica Thomas, Board Member
Costello Syndrome Family Network, Austin, TX, USA
Advocates’ Panel
Karin Walsh, PsyD
Children’s National Medical Center, WDC, USA
Pilot Trial of Effect of RAS/MAPK inhibitors on Neurocognitive Function in NF1
Brigitte Widemann, MD
National Cancer Institute, Bethesda, MD, USA
Symposium Co-Chair; Phase 1 Trial of AZD6244 in NF1 Tumo